Bonesupport Holding Past Earnings Performance
Past criteria checks 3/6
Bonesupport Holding has been growing earnings at an average annual rate of 55.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 34.6% per year. Bonesupport Holding's return on equity is 46.4%, and it has net margins of 40.6%.
Key information
55.7%
Earnings growth rate
54.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 34.6% |
| Return on equity | 46.4% |
| Net Margin | 40.6% |
| Next Earnings Update | 11 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bonesupport Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 656 | 267 | 498 | 59 |
| 31 Dec 23 | 591 | 245 | 462 | 57 |
| 30 Sep 23 | 522 | 214 | 418 | 54 |
| 30 Jun 23 | 448 | -30 | 383 | 54 |
| 31 Mar 23 | 382 | -51 | 342 | 53 |
| 31 Dec 22 | 329 | -68 | 312 | 53 |
| 30 Sep 22 | 287 | -72 | 279 | 53 |
| 30 Jun 22 | 257 | -71 | 249 | 51 |
| 31 Mar 22 | 234 | -82 | 236 | 53 |
| 31 Dec 21 | 213 | -86 | 221 | 53 |
| 30 Sep 21 | 205 | -88 | 212 | 55 |
| 30 Jun 21 | 198 | -96 | 214 | 55 |
| 31 Mar 21 | 182 | -92 | 197 | 54 |
| 31 Dec 20 | 181 | -101 | 201 | 58 |
| 30 Sep 20 | 174 | -115 | 207 | 60 |
| 30 Jun 20 | 165 | -127 | 204 | 66 |
| 31 Mar 20 | 166 | -151 | 227 | 68 |
| 31 Dec 19 | 155 | -161 | 226 | 69 |
| 30 Sep 19 | 132 | -166 | 213 | 68 |
| 30 Jun 19 | 108 | -191 | 215 | 67 |
| 31 Mar 19 | 98 | -182 | 199 | 68 |
| 31 Dec 18 | 97 | -176 | 192 | 66 |
| 30 Sep 18 | 101 | -182 | 181 | 68 |
| 30 Jun 18 | 119 | -146 | 163 | 65 |
| 31 Mar 18 | 128 | -132 | 148 | 66 |
| 31 Dec 17 | 129 | -129 | 150 | 61 |
| 30 Sep 17 | 132 | -112 | 153 | 56 |
| 30 Jun 17 | 126 | -124 | 154 | 54 |
| 31 Mar 17 | 114 | -124 | 160 | 42 |
| 31 Dec 16 | 105 | -110 | 140 | 38 |
| 31 Dec 15 | 62 | -60 | 88 | 19 |
| 31 Dec 14 | 41 | -75 | 61 | 17 |
Quality Earnings: 2B4 has a high level of non-cash earnings.
Growing Profit Margin: 2B4 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2B4 has become profitable over the past 5 years, growing earnings by 55.7% per year.
Accelerating Growth: 2B4 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 2B4 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 2B4's Return on Equity (46.4%) is considered outstanding.